Pliant Therapeutics Inc
PLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$66.25M
Close$
$0.27
75.3% downside
Current Fair Value
75.3% downsideOvervalued by 75.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $66.25 Million |
|---|---|
| Enterprise Value | $70.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 1.25 |
| Outstanding Shares | 61,919,233 |
Return
| Return on Equity | -62.81% |
|---|---|
| Return on Assets | -48.60% |
| Return on Invested Capital | -55.57% |
Valuation & Multiples
| P/E Ratio | -0.72 |
|---|---|
| PEG | 1.49 |
| Price to Sales | - |
| Price to Book Ratio | 0.54 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.73 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0840▲ 91.85% |
|---|---|
| Total Calls | 59,500▼ 62.13% |
| Total Puts | 124,000▼ 32.28% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.96%▲ 4.87% |
|---|---|
| Total Invested | $62.48M▲ 8.59% |
| Investors Holding | 94▼ 5.00% |
ESG Score
No data
About Pliant Therapeutics Inc
CEO: Bernard Coulie